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Abstract 
Background: In 2009, the Papua New Guinea (PNG) Department of Health adopted artemether–lumefantrine (AL) 
and dihydroartemisinin–piperaquine (DHA-PPQ) as the first- and second-line treatments for uncomplicated malaria, 
respectively. This study was conducted to assess the efficacy of both drugs following adoption of the new policy.
Methods: Between June 2012 and September 2014, a therapeutic efficacy study was conducted in East Sepik and 
Milne Bay Provinces of PNG in accordance with the standard World Health Organization (WHO) protocol for surveil-
lance of anti-malarial drug efficacy. Patients ≥ 6 months of age with microscopy confirmed Plasmodium falciparum 
or Plasmodium vivax mono-infections were enrolled, treated with AL or DHA-PPQ, and followed up for 42 days. Study 
endpoints were adequate clinical and parasitological response (ACPR) on days 28 and 42. The in vitro efficacy of anti-
malarials and the prevalence of selected molecular markers of resistance were also determined.
Results: A total of 274 P. falciparum and 70 P. vivax cases were enrolled. The day-42 PCR-corrected ACPR for P. falci-
parum was 98.1% (104/106) for AL and 100% (135/135) for DHA-PPQ. The day-42 PCR-corrected ACPR for P. vivax was 
79.0% (15/19) for AL and 92.3% (36/39) for DHA-PPQ. Day 3 parasite clearance of P. falciparum was 99.2% with AL and 
100% with DHA-PPQ. In vitro testing of 96 samples revealed low susceptibility to chloroquine (34% of samples above 
 IC50 threshold) but not to lumefantrine (0%). Molecular markers assessed in a sub-set of the study population indi-
cated high rates of chloroquine resistance in P. falciparum (pfcrt SVMNT: 94.2%, n = 104) and in P. vivax (pvmdr1 Y976F: 
64.8%, n = 54).
Conclusions: AL and DHA-PPQ were efficacious as first- and second-line treatments for uncomplicated malaria in 
PNG. Continued in vivo efficacy monitoring is warranted considering the threat of resistance to artemisinin and part-
ner drugs in the region and scale-up of artemisinin-based combination therapy in PNG.
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Background
The widespread resistance to commonly used 4-ami-
noquinolines continues to impede malaria control 
strategies in malaria-endemic countries. For decades 
the anti-malarial drugs chloroquine and sulfadoxine-
pyrimethamine were highly effective against falciparum 
malaria. However, due to the emergence of resistant 
Plasmodium falciparum and Plasmodium vivax parasite 
strains [1], the World Health Organization (WHO) now 
recommends a 3-day course of artemisinin-based combi-
nation therapy (ACT), which has a proven high efficacy 
[2]. By administering a 3-day regimen, the concentra-
tion of both drugs is effective enough to kill the eryth-
rocytic stages of the parasite [3]. Moreover, the risk of a 
spread of strains resistant to artemisinin derivatives is 
minimized by the partner drug. In line with WHO rec-
ommendations, Papua New Guinea (PNG) introduced 
a new anti-malarial treatment guideline in 2009 with 
artemether–lumefantrine (AL) and dihydroartemisinin–
piperaquine (DHA-PPQ) as the first-and second-line 
treatments, respectively [4, 5]. A comparative treatment 
trial conducted in PNG children had found AL to be the 
most efficacious treatment against P. falciparum and 
DHA-PPQ most efficacious against P. vivax [6]. The 
country-wide roll-out of AL to public health facilities 
started 2 years after policy adoption, in late 2011 [7].
Unfortunately, there is increasing resistance of para-
sites to ACT in the Greater Mekong Region [4, 8, 9], a 
region that is well known for the development of anti-
malarial drug resistance. Recently, alarming rates of 
resistance to DHA-PPQ have been reported in Cambodia 
[10]. In order to protect the efficacy of ACT drug efficacy, 
monitoring is considered an essential aspect of malaria 
control programmes in all endemic countries [11, 12].
A therapeutic efficacy study was conducted in PNG 
with the primary objective of assessing the in vivo efficacy 
of AL and DHA-PPQ after their introduction. Secondary 
objectives included measuring the in vitro efficacy  (IC50) 
of a range of anti-malarial drugs used in PNG and inves-
tigating the prevalence of molecular markers associated 
with in vivo failures.
Methods
Study sites
This study was conducted in 2 sites in PNG (Maprik, 
East Sepik Province, and Alotau, Milne Bay Province) 
from 2012 to 2014 following the standard WHO proto-
col for surveillance of anti-malarial drug efficacy [13]. In 
Maprik, patients were recruited from Ilahita Health Cen-
tre and the Sunuhu and Malahum aid posts. In Alotau, 
patients were recruited from Gurney Health Centre, Alo-
tau General Hospital Children’s Outpatient Department, 
Goilanai Urban Clinic, Hagita Estate Health Centre, and 
from the Gabugabuna and Naura Aid Posts.
Patient enrolment and follow‑up
Patients aged ≥ 6  months presenting with fever 
(≥ 37.5  °C) or a history of fever in the previous 72  h at 
one of the study health facilities were initially screened 
and enrolled provided they had: (i) weight ≥ 5.0  kg; (ii) 
Hb ≥ 5.0 g/dL; (iii) easy access to the study facility to ena-
ble follow-up; (iv) positive malaria rapid diagnostic test 
(RDT; CareStart Malaria Combo, Access Bio, USA); and, 
(v) microscopy-confirmed P. falciparum (≥ 1000 para-
sites/μL) or P. vivax (≥ 250 parasites/μL) mono-infection. 
Patients with signs of severe malaria and other exclusion 
criteria were referred to health facility staff for clinical 
management according to routine practice. Patients were 
enrolled and allocated to either the AL or DHA-PPQ 
treatment arm. Due to a delay in the arrival of the sec-
ond-line drug (DHA-PPQ) in the country, the AL treat-
ment arm was started first followed by the DHA-PPQ 
arm a year later. Patients were initially enrolled on a pro-
visional basis based on their RDT result and treated with 
AL or DHA-PPQ. After confirmatory diagnosis by light 
microscopy, only patients meeting the above inclusion 
criteria were retained in the study. RDT-positive cases 
that had parasite counts below the required threshold or 
mixed species infections were excluded while a complete 
treatment course was provided.
Active follow-up was performed by study nurses on 
days 1, 2, 3, 7, 14, 28, and 42. During enrolment and 
follow-up visits, clinical and physical examinations were 
performed and the findings were recorded in case report 
forms. Blood slides and filter paper samples were col-
lected in all visits while haemoglobin levels were meas-
ured on days 0, 7, 14, 28, and 42 using a hand-held 
Hemocue device (Hb201+, Hemocue, Sweden).
Drugs administration
Patients enrolled into the AL arm were treated with 6 
doses of  Coartem® tablets (Novartis Pharma, Switzer-
land) containing 20  mg of artemether and 120  mg of 
lumefantrine over 3  days, administered with 250  mL of 
milk. Doses were allocated by weight group: 5.0–14.9 kg 
1 tablet; 15.0–24.9  kg 2 tablets; 25.0–34.9  kg 3 tablets; 
and ≥ 35.0  kg 4 tablets. All doses were administered 
under direct supervision by a study nurse. For patients 
enrolled into the DHA-PPQ arm,  Eurartesim® film-
coated tablets (Sigma-tau Pharma Limited, Rome, Italy) 
containing 40  mg of DHA and 320  mg of PPQ were 
administered with water under supervision once daily for 
3  days. Doses were allocated according to the following 
weight groups: 7.0 to < 13.0 kg ½ tablet; 13.0 to < 24.0 kg 
1 tablet; 24.0 to < 36.0  kg 2 tablets; 36.0 to < 75.0  kg 3 
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tablets; 75.0–100.0  kg 4 tablets. The dosage schedules 
were in accordance with the National Malaria Treatment 
Protocol [5]. Participants who vomited within 30 min of 
treatment administration were re-administered the dose 
from a spare blister. Participants who were parasitaemic 
during a follow-up visit were excluded and referred to the 
study health facility for treatment, while the study team 
ensured that all participants were eventually completely 
cured.
Laboratory procedures
Light microscopic diagnosis was conducted indepen-
dently by 2 WHO-certified Level 1 to Level 3 micros-
copists at the Papua New Guinea Institute of Medical 
Research (PNGIMR) in Madang. In case of discordant 
results, slides were examined by a third senior microsco-
pist (WHO Level 1 certified). A minimum of 200 thick 
film fields were examined before a slide was declared 
negative and a patient was considered aparasitaemic if no 
parasites were found by two microscopists. The number 
of parasites was counted up to 200 white blood cells (par-
asite count > 100/field) or 500 white blood cells (parasite 
count < 100/field). Parasite counts for each species were 
converted to the number of parasites per μL of blood 
assuming 8000 white blood cells per μL [11].
Polymerase chain reaction (PCR) assays were used 
to distinguish recrudescence from re-infection cases 
using Pfmsp2 for P. falciparum and Pvmsp1 for P. vivax 
[14–17]. Length polymorphisms of the fragments of 
Pfmsp2, Pvmsp1F3 and Pvms16 were determined using 
capillary electrophoresis at Macrogen (South Korea). The 
data obtained from GeneScan (Thermo Fisher Scientific, 
Waltham, MA, USA) were analysed using GeneMarker, 
version 2.4.0 (Soft Genetics, State College, PA, USA). 
The method used for P. vivax allows discrimination 
between strains in post-treatment recurrent infections 
in a way analogous to that established for falciparum 
malaria. Although P. vivax genotyping cannot differenti-
ate between a recrudescent infection and a relapse with 
the same genotype, based on previous observations, most 
relapses are genetically distinct from the primary infec-
tions [14, 15, 17].
A ligase detection reaction-fluorescent microsphere 
assay (LDR-FMA) method, which has been described 
in detail elsewhere [14, 16, 17], was used for genotyping 
anti-malarial resistance markers. This study focussed on 
the presence of single point mutations for the P. falcipa-
rum chloroquine-resistance transporter gene (pfcrtK76T) 
and the P. falciparum multi-drug resistance-1 (pfmdr-
1N86Y, Y184F, S1034C, N1042D & D1246Y) as well as 
the P. vivax multi-drug resistance-1 (pvmdr-1Y976F) 
genes. PfK13 for artemisinin and Pfplasmepsin 2/3 for 
piperaquine resistance were not assessed as this study 
was carried out before the discovery of these markers.
Plasmodium falciparum cultures were maintained 
using a modified candle-jar technique based on the 
Trager & Jensen method for culture of P. falciparum 
parasites [18]. The anti-malarial drugs used in this assay 
were chloroquine, lumefantrine, naphthoquine, pipe-
raquine, and pyronaridine. The plates were set up as pre-
viously described [19], with modifications.
Study outcomes
The treatment outcomes were categorized according to 
WHO guidelines [13] as early treatment failure (ETF): 
having danger signs or complicated malaria with evi-
dence of persistent parasitaemia and fever (≥ 37.5 °C) on 
the first 3  days of treatment; late clinical failure (LCF), 
defined as the detection of recurrent parasitaemia with 
fever (≥ 37.5  °C) between day 4 and day 28 (day 42) 
without meeting any criteria of ETF; late parasitologi-
cal failure (LPF): the detection of parasitaemia between 
day 7 and day 28 (day 42) but with no signs of sympto-
matic malaria; and, adequate clinical and parasitological 
response (ACPR) where the treatment is completed suc-
cessfully with no confirmed re-infection on day 28 (day 
42) and without meeting previous criteria of ETF, LCF 
or LPF. The overall treatment failure was considered as 
the sum of the ETF, LCF and LPF. Fever clearance was 
defined as proportion of patients whose body tempera-
ture decreased below 37.3 °C after drug intake on days 1, 
2 and 3. Parasite clearance was defined as the proportion 
of patients with a negative blood slide after drug intake 
on days 1, 2 and 3.  IC50 values are the concentration of a 
particular drug at which 50% of the parasites is inhibited 
in vitro. The prevalence of molecular markers was calcu-
lated as the frequency of any of the single nucleotide pol-
ymorphisms (SNPs) within the key resistance molecular 
markers (pfcrt, pfmdr1 and pvmdr1).
Statistical methods
The sample size calculation for this study was based on 
an expected 5% failure rate of P. falciparum, a 95% level 
of confidence and 5% precision. An additional 20% was 
added to account for patients who would be lost dur-
ing follow-up, violate protocol or voluntarily withdraw, 
resulting in a total sample size of 88 patients per arm 
per site, allowing site-specific efficacy estimation. Due to 
the unpredictability of the incidence of P. vivax mono-
infections, no formal sample size was performed for 
including P. vivax cases. Instead, the study would recruit 
all patients with P. vivax up until the total P. falciparum 
sample size was reached.
Case report forms were entered using REDCap (Research 
Electronic Data Capture; http://proje ct-redca p.org/). 
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Analysis of study outcomes was based on a per-protocol 
analysis of pooled patient data from both study sites, which 
excluded cases with a Plasmodium species other than P. fal-
ciparum or P. vivax, protocol violations, and patients lost to 
follow-up. Statistical analysis was carried out using STATA 
11.0 (StataCorp, Texas, USA). Statistically significant dif-
ferences in rates of treatment response outcomes, both for 
PCR-corrected and PCR-uncorrected, as well as in baseline 
characteristics were assessed using Chi square tests and 
non-parametric tests for not normally distributed data. 
Fever and parasite clearance rates were compared using 
Fisher’s exact test. Fever was defined as axillary tempera-
ture of ≥ 37.5  °C for enrolment and a 37.3  °C cut-off was 
used to define fever clearance.
Results
Baseline characteristics
A total of 2918 patients with fever (≥ 37.5 °C), or a recent 
history of fever, were screened at the health facilities in 
Maprik and Alotau between June 2012 and September 
2014 (Fig.  1). Of these, 33.8% (987/2918) had a positive 
RDT and 42.2% (417/987) were initially enrolled on a 
provisional basis and sequentially allocated to either the 
AL or DHA-PPQ study arm. Out of the provisionally 
enrolled patients, 17.5% (73/417) were excluded post hoc, 
including 49.3% (36/73) due to too low parasite counts, 
32.9% (24/73) were negative by microscopy, while 17.8% 
(13/73) were mixed infections or Plasmodium malariae.
In total, 344 patients (age range 0.5–64  years) were 
finally enrolled and followed-up according to the study 
protocol (171 in Alotau and 173 in Maprik). Out of the 
P. falciparum cases in the AL arm, 19 were excluded 
between day 0 and 28 (7 lost to follow-up, 11 protocol 
violations, 1 voluntary withdrawal) and 4 between day 
28 and 42 (2 protocol violations, 2 lost to follow-up). Of 
the P. falciparum cases in the DHA-PPQ arm, 7 were 
excluded between day 0 and 28 (3 protocol violations, 3 
lost to follow-up, 1 voluntary withdrawal) and 3 were lost 
to follow-up between day 28 and 42. Of the P. vivax cases 
in the AL arm, 5 were excluded between day 0 and 28 (1 
protocol violation, 4 lost to follow-up) and 4 between 
day 28 and 42 (3 lost to follow-up, 1 protocol viola-
tion). Of the P. vivax cases in the DHA-PPQ arm, 1 was 
excluded due to protocol violation between day 0 and 28, 
while 2 were lost to follow-up between day 28 and 42. 
A comparison of the two study populations is provided 
in Additional file  1: Table  S1. On average, patients in 
Maprik were younger (mean age 5.6 years vs 7.9 in Alo-
tau, P < 0.001), lighter (mean weight 16.1  kg vs 20.7  kg, 
P < 0.001), had a higher prevalence of splenomegaly (49.7 
vs 28.1%, P = 0.001) and a lower mean haemoglobin con-
centration (8.6 g/dL vs 10.5 g/dL, P < 0.001).
Overall, 79.7% (274/344) of all enrolled patients were 
infected with P. falciparum and 20.3% (70/344) with P. 
vivax. Of the patients with falciparum malaria, 47.1% 
(129/274) were treated with AL while 52.9% (145/274) 
received DHA-PPQ. Of those treated with AL, 85.3% 
(110/129) and 82.2% (106/129) had clinical and PCR-
corrected data on days 28 and 42, respectively. Of 
the DHA-PPQ-treated patients, 95.2% (138/145) and 
93.1% (135/145) had clinical and PCR-corrected data 
on days 28 and 42, respectively. Of the patients with 
vivax malaria, 40% (28/70) were treated with AL and 
60% (42/70) with DHA-PPQ. Of those treated with AL, 
82.1% (23/28) and 67.9% (19/28) had clinical and PCR-
corrected data on days 28 and 42, respectively, while 
97.6% (41/42) and 92.9% (39/42) of DHA-PPQ-treated 
patients had the respective data available (Fig. 1).
Patients enrolled into the AL and DHA-PPQ treat-
ment arms were comparable with regard to most base-
line demographic and anthropometric characteristics 
(gender, weight, mid-upper-arm circumference, Hb, 
parasite density, enlarged spleen; Table  1). However, 
there was a significant baseline difference (P = 0.009) 
in body temperature between the AL and DHA-PPQ-
treated patients with vivax malaria. In addition, the 
median parasite density in patients with falciparum 
malaria was significantly higher in the DHA-PPQ arm 
compared to the AL arm (P < 0.001).
Drug efficacy
Nine of the 274 patients infected with P. falciparum 
at enrolment (N = 274) experienced a treatment fail-
ure by day 42. Of these, 8 were classified as LPF (3 in 
the DHA-PPQ arm and 6 in the AL arm) while 1 was 
a LCF in the AL arm (Table  2). After PCR correction 
for re-infection, the day-28 ACPR was 100% in both the 
AL (110/110) and DHA-PPQ (138/138) arms (Table 3). 
At day 42 it was 98.1% (104/106) for AL and 100% 
(135/135) for DHA-PPQ (P = 0.11).
Fourteen of the 70 patients infected with P. vivax at 
enrolment had a treatment failure by day 42 (9 in the 
AL arm and 5 in the DHA-PPQ arm; Table  2), most 
with LPF. After PCR correction for re-infection 7 
remained positive. The PCR-corrected ACPR at day 28 
was 95.7% (22/23) for AL, all LPF, and 100% (41/41) for 
DHA-PPQ (P = 0.18). At day 42, PCR-corrected ACPR 
was 78.9% (15/19) for AL and 92.3% (36/39) for DHA-
PPQ (P = 0.14) (Table  3). Day-28 PCR-uncorrected 
ACPR was 87% (20/23) and 100% (41/41) for AL and 
DHA.PPQ, respectively (P = 0.06), while at day 42 it 
was 68.4% (13/19) for AL and 87.2% (34/39) for DHA-
PPQ (P = 0.23; Table 2).
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Fever and parasite clearance
Fevers were cleared rapidly with the vast majority of 
patients being parasite free by day 3 but a significantly 
higher proportion of P. falciparum patients was still 
febrile on day 1 after treatment with AL as com-
pared to DHA-PPQ (odds ratio = 1.88, Fisher’s Exact 
Fig. 1 Screening, enrolment, treatment, and follow-up of study patients from Maprik and Alotau, Papua New Guinea, June 2012–September 2014
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Test P = 0.008). However, all fevers in both P. falcipa-
rum- and P. vivax-infected patients in the AL arm had 
cleared by day 3. One patient with P. vivax in the DHA-
PPQ arm presented with fever at every time point post 
treatment (day 0–day 7). One patient with P. falcipa-
rum in the DHA-PPQ arm had fever on day 2 and then 
on day 7. However, all these fevers were most likely not 
associated with the parasite infection as all parasites 
were cleared in these patients and there were no fevers 
on day 1 (Table 4, Fig. 2).
Haemoglobin
In the AL treatment arm, the mean Hb concentra-
tion increased from 9.6 g/dL in patients with P. falcipa-
rum and 9.7  g/dL in patients with P. vivax on day 0 to 
10.7 days/dL and 10.2 days/dL on day 42, respectively. Hb 
Table 1 Baseline characteristics of  patients according to  treatment arms with  Plasmodium falciparum and  Plasmodium 
vivax infections
AL artemether–lumefantrine, DHA-PPQ dihydroartemisinin–piperaquine
Characteristics P. falciparum (N = 274) P. vivax (N = 70)
AL DHA‑PPQ P‑value AL DHA‑PPQ P‑value
Males (%) 48 52 0.74 40 60 > 0.99
Mean age (years) 6.5 8.2 0.04 4.5 4.0 0.53
Mean weight (kg) 18.7 19.9 0.33 15.2 14.0 0.53
Mean MUAC (cm) 17.2 17.5 0.48 16.5 16.5 > 0.95
Parasite density/µL
 Median 13,639 26718 < 0.0001 2835 6302 0.07
 Range 1058–26,373 1133–261,992 831–157,339 305–86,666
 Mean temperature (°C) 37.8 37.5 0.08 37.7 36.9 0.009
 Enlarge spleen (%) 48.7 51.3 0.65 47.4 52.6 0.59
 Mean Hb (g/dL) 9.5 9.5 >0.95 9.7 9.5 0.58
Table 2 Per-protocol secondary endpoint analysis of  treatment responses in  cases with  Plasmodium falciparum 
or Plasmodium vivax for PCR-uncorrected malaria
AL DHA‑PPQ Total P‑value
P. falciparum assessed at day 28, n 110 138 248
 Adequate clinical and parasitological response, n (%) [95% CI] 108 (98.2) [92.9–99.7] 138 (100) [96.6–100] 246 (99.2) − 0.28
 Early treatment failure, % 0 0 0 –
 Late clinical failure, % 0.9 0 0.4 –
 Late parasitological failure, % 0.9 0 0.4 –
P. falciparum assessed at day 42, n 106 135 241
 Adequate clinical and parasitological response, n (%) [95% CI] 102 (96.2) [90.07–98.8] 132 (97.8) [93.2–99.4] 234 (97.1) 0.48
 Early treatment failure, % 0 0 0 –
 Late clinical failure, % 0 0 0 –
 Late parasitological failure, % 3.8 2.2 2.9 –
P. vivax assessed day 28, n 23 41 64
 Adequate clinical and parasitological response, n (%) [95% CI] 20 (87.0) [65.3–96.6] 41 (100) [89.3–100] 61 (95.3) 0.06
 Early treatment failure, % 0 0 0 –
 Late clinical failure, % 4.3 0 1.6 –
 Late parasitological failure, % 8.7 0 3.1 –
P. vivax assessed day 42, n 19 39 58
 Adequate clinical and parasitological response, n (%) [95% CI] 13 (68.4) [43.5–86.4] 34 (87.2) [71.8–95.2] 47 (81.03) 0.23
 Early treatment failure, % 0 0 0 –
 Late clinical failure, % 10.5 5.1 6.9 –
 Late parasitological failure, % 21.1 7.7 5.3 –
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levels in P. vivax patients appeared to increase faster than 
in P. falciparum patients (Additional file 2: Figure S1). In 
the DHA-PPQ arm, a decrease in mean Hb was observed 
on day 7 (8.8 g/dL in P. falciparum, 9.2 g/dL in P. vivax), 
followed by an increase on subsequent days. In all groups, 
day 42 mean Hb concentration was higher than on day 0 
and no participant had developed severe anaemia (< 8 g/
dL) over the course of the treatment.
Adverse events
Both treatments were generally well tolerated. The 
overall frequency of adverse events was 56.1% (88/157) 
in the AL arm and 60.4% (113/187) in the DHA-PPQ 
arm (P = 0.443) (Table  5). The most frequent adverse 
events were cough (38.2% in AL; 38% in DHA-PPQ), 
running nose (12.1% in AL; 21.9% DHA-PPQ) and 
headache (10.2% AL and 18.7% DHA-PPQ). Headache 
Table 3 Per-protocol primary endpoint analysis of  treatment responses in  cases with  Plasmodium falciparum 
or Plasmodium. vivax for PCR-corrected malaria
AL DHA‑PPQ Total P‑value
P. falciparum assessed at day 28, n 110 138 248
 Adequate clinical and parasitological response, n (%) [95% CI] 110 (100) [95.8–100] 138 (100) [96.6–100] 248 (100) –
 Early treatment failure, % 0 0 0 –
 Late clinical failure, % 0 0 0 –
 Late parasitological failure, % 0 0 0 –
P. falciparum assessed at day 42, n 106 135 241
 Adequate clinical and parasitological response, n (%) [95% CI] 104 (98.1) [92–99.7] 135 (100) [96.6–100] 239 (99.2) − 0.11
 Early treatment failure, % 0 0 0 –
 Late clinical failure, % 0 0 0 –
 Late parasitological failure, % 1.9 0 0.8 –
P. vivax assessed day 28, n 23 41 64 –
 Adequate clinical and parasitological response, n (%) [95% CI] 22 (95.7) [76.03–99.8] 41 (100) [89.3–100] 63 (98.4) 0.18
 Early treatment failure, % 0 0 0 –
 Late clinical failure, % 0 0 0 –
 Late parasitological failure, % 4.3 0 1.6 –
P. vivax assessed day 42, n 19 39 58 –
 Adequate clinical and parasitological response, n (%) [95% CI] 15 (78.9) [53.9–93.03] 36 (92.3) [78.03–98.0] 51 (87.9) 0.14
 Early treatment failure, % 0 0 0 –
 Late clinical failure, % 5.3 0 1.7 –
 Late parasitological failure, % 15.8 7.7 10.3 –
Table 4 Proportion of patients with no detectable parasites grouped by malaria species and treatment arm
Values are presented as % (n/N)
* Fisher’s exact test
** Fever clearance was defined as axillary temperature < 37.3 °C after two consecutive events with ≥ 37.3 °C starting from day 0
P. falciparum P. vivax
AL DHA‑PPQ P‑value* AL DHA‑PPQ P‑value*
A) Fever clearance**
 Day 1 88.2 (60/68) 100 (64/64) 0.008 92.9 (13/14) 90.1 (10/11) 1.00
 Day 2 95.6 (65/68) 98.4 (63/64) 0.62 92.9 (13/14) 90.1 (10/11) 1.00
 Day 3 100 (68/68) 96.9 (62/64) 0.24 100 (14/14) 90.1 (10/11) 0.46
 Day 7 100 (68/68) 98.4 (63/64) 0.49 100 (14/14) 90.1 (10/11) 0.46
B) Parasite clearance
 Day 1 64.3 (83/129) 70 (101/145) 0.7 92.9 (26/28) 90.5 (38/42) 1.00
 Day 2 96.1 (124/129) 100 (142/142) 0.93 100 (28/28) 100 (42/42) 1.00
 Day 3 99.2 (128/129) 100 (143/143) 1.00 100 (28/28) 100 (42/42) 1.00
 Day 7 100 (129/129) 99 (141/142) 1.00 100 (28/28) 100 (42/42) 1.00
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and running nose were significantly more frequently 
reported in patients in the DHA-PPQ arm (P = 0.033 
and P = 0.022, respectively). The observed adverse 
events are common signs related to the underlying dis-
ease (malaria) and are likely not a result of the study 
drugs. There were neither severe adverse events nor 
any deaths during the study.
Molecular markers of resistance
Out of a total of 274 P. falciparum cases, 104 had a 
pfcrt LDR-FMA confirmed result. The single mutant 
haplotype (SVMNT) was found in 96 (92.3%) samples, 
the polyclonal CVMNK/SVMNT mutant haplotype in 
2 (1.9%), and the wild type (CVMNK) in 6 (5.8%) cases 
and 2 (1.9%) exhibited the polyclonal CVMNK/SVMNT 
mutant haplotype. Out of the two confirmed LPF in P. 
falciparum patients on day 42, one carried the SVMNT 
mutation. The genotype of the second patient could not 
be determined. Three cases treated with DHA-PPQ had 
a SVMNT mutation with 1 exhibiting a chloroquine 
 IC50 value of 122  nM. The only polyclonal (CVMNK/
SVMNT) isolate that was treated with AL had a chloro-
quine  IC50 of 67.5 nM.
For pvmdr1, the Y976F mutation was assessed. A 
total of 54 samples were successfully typed of which 19 
(35.2%) were wild type (Y), 26 (48.1%) were mutant (F) 
and 9 (16.7%) were mixed wild type mutant (YF). Of the 
6 P. vivax cases that had LPF at day 42 (3 from each treat-
ment arm), 2 were wild type, 2 were mutant, 1 was mixed 
wild type/mutant and 1 was undetermined. The only LCF 
with P. vivax and treated with AL was a mutant.
In vitro drug susceptibility
A total of 49 P. falciparum parasite isolates from Maprik 
and 47 from Alotau were collected at enrolment were 
tested for in  vitro sensitivity to chloroquine, lumefan-
trine, naphthoquine, piperaquine, and pyronaridine. 
The mean drug concentration required for 50% parasite 
growth inhibition in vitro  (IC50) is provided in Table 6. In 
total, 34% (33/96) of the chloroquine assays had an  IC50 
value above the ≥ 100 nM cut-off, while all lumefantrine 
had  IC50 values below their ≥ 150  nM cut-off threshold. 
Fig. 2 Graphic representation parasite clearance (as in Table 4B).*Indicates a statistically significant difference between treatment groups
Table 5 Most frequent adverse events after  28  days 
of treatment
Values are presented n (%)
* Fisher’s exact test
Adverse events AL DHA‑PPQ P‑value*
(N = 157) (N = 187)
Patients with at least one 
adverse event
87 (55.4) 112 (59.9) 0.443
Abdominal pain 17 (10.8) 10 (5.3) 0.071
Chills 12 (7.6) 15 (8.0) 1.0
Cough 60 (38.2) 71 (38.0) 1.0
Diarrhoea 11 (7.0) 8 (4.3) 0.345
Headache 16 (10.2) 35 (18.7) 0.033
Vomit 4 (2.5) 6 (3.2) 0.760
Ear pain 3 (1.9) 2 (1.1) 0.663
Running nose 19 (12.1) 41 (21.9) 0.022
Skin rash 1 (0.6) 2 (1.1) 1.0
Shortness of breath 1 (0.6) 2 (1.1) 1.0
Fits 1 (0.6) 2 (1.1) 1.0
Stiff neck 1 (0.6) 1 (0.5) 1.0
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No cut-off values for piperaquine and pyronaridine were 
available in literature.
There were no significant differences observed between 
the two study sites in the geometric mean  IC50 to any 
anti-malarials tested (P for all > 0.05). For the two PCR 
confirmed LPF with P. falciparum (day 42) in the AL 
treatment arm, no in vitro assays were performed.
A further comparison was undertaken between in vitro 
drug susceptibility data collected in Madang between 
2011 and 2013 [20] and those generated in the present 
study. The comparison is also shown in Table  6. The 
assays were carried out under comparable conditions 
using the same study drugs. Geometric mean  IC50 values 
for naphthoquine and lumefantrine differed significantly. 
Both drugs seemingly exhibited a lower susceptibility in 
the present study as compared to the previous trial in 
Madang.
Discussion
This therapeutic efficacy study conducted across all age 
groups in two sites of PNG confirms high efficacy of the 
current first- and second-line anti-malarial treatments, 
AL and DHA-PPQ, for uncomplicated malaria. No recru-
descence was found within 42 days in patients with fal-
ciparum malaria treated with DHA-PPQ but 2 (1.9%) 
patients treated with AL experienced LPF. ACPR in AL-
treated patients was comparable to two other studies 
carried out in children aged 0.5–5 years in Madang and 
East Sepik provinces (Karunajeewa et  al. day 42 ACPR 
95.2% [6]; Laman et al. day 42 ACPR 97.8% [11]. The two 
recrudescent infections observed in the AL arm on day 
42 underline the importance of continued monitoring 
of the efficacy of AL in the context of increasing use of 
the regimen in public facilities and persisting availability 
of monotherapy [21]. ACPR to DHA-PPQ was higher in 
this study (day 42: 97.8%, 95% CI 93.2–99.4) than in the 
previous trial conducted by Karunajeewa et al. in 2005–
2007 (day 42: 88%, 95% CI 80–93.6) [6]. The 95% confi-
dence intervals of the ACPR of both drugs remain well 
above the 90% minimum efficacy threshold defined by 
WHO [2].
The interpretation of the efficacy against P. vivax 
cases is compromised mainly by the inherent difficulty 
of unambiguously distinguishing recrudescences from 
relapses and re-infections. PCR-uncorrected ACPR on 
day 42 was 68.4% (95% CI 43.5–86.4) in patients treated 
with AL and 87.2% (95% CI 71.8–95.2) in patients treated 
with DHA-PPQ. ACPR was higher in this study than pre-
viously reported for AL (30.3%, 95% CI 15.6–48.7) and 
DHA-PPQ (69.4%, 95% CI 51.9–83.7) in the study by 
Karunajeewa et  al. [6]. Of all P. vivax cases with recur-
rent parasitaemia on day 42, 33.3% in the AL group and 
40% in the DHA-PPQ group were identified as infections 
with new genotypes suggestive of a re-infection or 
relapse rather than recrudescence. The resulting PCR-
corrected ACPR of both treatment regimens in this study 
remained above 90% on day 28 and on day 42 in the case 
of DHA-PPQ; however, confidence intervals spanned 
across the 90% efficacy threshold generally applied for P. 
falciparum. As genotyping cannot differentiate between 
true recrudescence and relapses from hypnozoites with 
the same genotype, the PCR-corrected ACPR values for 
P. vivax need to be interpreted with caution. At day 28, 
there were 4.3% treatment failures seen in the AL group 
but none in DHA-PPQ. While these results may be indic-
ative of a higher efficacy of DHA-PPA against P. vivax, 
as suggested in a previous study to be likely due to the 
longer half-life of the partner drug PPQ [6] this was not 
statistically significant in the present study as it was not 
powered for such comparison.
This study further assessed parasite and fever clearance 
time over the first 7 days in order to detect any delayed 
treatment response. Day 3 parasite clearance after treat-
ment with an ACT has been suggested by WHO as a 
proxy indicator for artemisinin resistance of P. falcipa-
rum. An increased parasite clearance time with ≥ 10% of 
cases with detectable P. falciparum parasites on day 3 is 
the current working definition of suspected artemisinin 
resistance [9]. This study found high parasite and fever 
clearance rates in patients infected with P. falciparum or 
P. vivax in both treatment groups, confirming the general 
observation that both, AL and DHA-PPQ are still highly 
efficacious treatments in PNG.
The drop in Hb concentration observed in P. falcipa-
rum patients treated with DHA-PPQ may be explained 
by the higher average parasite density in this study group 
(mean density in P. falciparum patients AL 19,298 para-
sites/μL vs DHA-PPQ 41,282 parasites/μL; P < 0.001; 
mean density in P. vivax patients AL 10,229 parasites/μL 
vs DHA-PPQ 9356 parasites/μL; P = 0.87). On the other 
hand, a decrease in Hb in patients treated with DHA-
PPQ had previously been observed in other studies and 
further investigations may hence be warranted [6].
There were no significant differences in in  vitro effi-
cacy of the tested drugs between the study sites (Alotau 
and Maprik). A recent study using the same assay con-
ducted in Madang [20] found similar  IC50 values. When 
comparing the results from this study with a previous 
study carried out in Madang 5 years ago [22], differences 
were observed in  IC50 in Madang and Alotau or Maprik, 
respectively, were: chloroquine (167 nM vs 69 nM), pipe-
raquine (27.7 nM vs 21 nM), and lumefantrine (1.55 nM 
vs 6.92  nM). Further studies are required to determine 
if these differences are due to the use of a different assay 
(Sybr green in this study vs pLDH in the previous study). 
In addition, the lower  IC50 values of chloroquine seen 
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in this study could possibly be an early indication of 
decreased parasite resistance pressure due to the shelving 
of chloroquine in PNG over the past 6 years.
The mutations in the pfcrt gene however remained near 
fixation (> 95% of samples had mutant pfcrt). Mutations 
in the pfmdr gene were also widespread with 68% of iso-
lates carrying the N86Y mutation with other mutations 
in pfmdr being rare or absent. These results are in accord-
ance with the prevalence of molecular markers of resist-
ance as shown in earlier studies [20, 22] and indicate that 
chloroquine resistance is likely to still be widespread in 
PNG. The Y976F mutation has previously been associ-
ated with P. vivax chloroquine resistance in Melanesia 
[23]. The higher prevalence of this mutation thus indi-
cated that P. vivax chloroquine resistance is likely to be 
common in PNG, thus justifying the use of ACT as first-
line treatments against both P. falciparum and P. vivax.
Implementing this study was faced with operational 
challenges as only a few centres in PNG are equipped for 
conducting therapeutic efficacy studies. Furthermore, 
the start of enrolment coincided with a large-scale free 
distribution of long-lasting insecticidal nets in the study 
sites which led to a reduction in the number of malaria 
cases presenting to the health facilities [24]. A consid-
erable number of malaria-positive patients had to be 
excluded from this study due to low parasite counts mak-
ing it difficult to recruit a sufficient number of patients 
for the efficacy study. The final sample size reached did 
not allow an independent assessment by site but was 
sufficient for a pooled analysis. Routine in  vivo treat-
ment efficacy monitoring hence remains challenging in 
PNG. Over the last 2 years molecular markers of resist-
ance to artemisinin (i.e., SNPs in the kelch 13 gene [25] 
and piperaquine (amplification of plasmepsin 2/3) have 
been validated and an increase in pfmdr1 86Y wild type 
alleles have been implicated in increased resistance to AL 
[26]. These molecular markers thus provide an easier and 
cheaper alternative that allows continuous monitoring of 
resistance across numerous locations in PNG.
Conclusions
The results from this study have shown that AL and 
DHA-PPQ remain efficacious for the treatment of 
uncomplicated falciparum and vivax malaria in PNG. 
Based on the day-3 parasite clearance rate, there is no 
evidence of artemisinin resistance in the two study sites. 
Continued monitoring of anti-malarial drug efficacy is 
warranted considering increasing use of ACT in routine 
clinical practice, the persistence of artemisinin mono-
therapy in the system and the presence of artemisinin 
resistance in neighbouring regions. Regular molecular 
monitoring of resistance markers may be a more cost-
effective alternative to the considerable investments 
necessary to conduct therapeutic efficacy studies in new 
or additional study sites in PNG.
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